AstraZeneca breast cancer drug fails trial but Citi keeps 'buy' rating

Data ReadoutnegativeNegative

AI Analysis

Summary

AstraZeneca's breast cancer drug failed its clinical trial, though Citigroup maintained a 'buy' rating on the company. The analyst's continued positive stance suggests confidence in the company's broader pipeline despite the setback.

Clinical Trial Data

Primary Endpoint

Not Met

Outcome Details

breast cancer drug failed trial

Importance:7/10

Sentiment:

-0.60

Phase 3trial failurebreast canceroncology

Related Companies

$AZN

Read the original article

Published by yahoo_finance on September 14, 2026 12:01 PM

Read Original